Swedish image analysis software developer AMRA Medical has announced that its whole-body MRI image analysis software performed well in a recent clinical trial.
The phase IIB trial, launched by Fulcrum Therapeutics in 2019, tested the safety and efficacy of losmapimod, a treatment for patients with facioscapulohumeral muscular dystrophy. The study enrolled 80 patients across 17 sites in four countries.
Participants were assessed with AMRA's quantitative full-body, whole-muscle MRI software. Losmapimod-treated participants showed decreased disease progression in the composite measure of muscle fat infiltration, as measured in intermediate muscles, AMRA said.
The results demonstrate how MRI advancements can detect pathological changes in muscle and provide information about disease severity, disease progression, and the effect of a drug on muscle health, AMRA said.
